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Rett syndrome (RTT) is an inherited neurodevelopmental disor-
der of females that occurs once in 10,000–15,000 births1,2.
Affected females develop normally for 6–18 months, but then
lose voluntary movements, including speech and hand skills.
Most RTT patients are heterozygous for mutations in the X-
linked gene MECP2 (refs. 3–12), encoding a protein that binds
to methylated sites in genomic DNA and facilitates gene silenc-
ing13–17. Previous work with Mecp2-null embryonic stem cells
indicated that MeCP2 is essential for mouse embryogenesis18.
Here we generate mice lacking Mecp2 using Cre-loxP technol-
ogy. Both Mecp2-null mice and mice in which Mecp2 was
deleted in brain showed severe neurological symptoms at
approximately six weeks of age. Compensation for absence of
MeCP2 in other tissues by MeCP1 (refs. 19,20) was not apparent
in genetic or biochemical tests. After several months, heterozy-
gous female mice also showed behavioral symptoms. The over-
lapping delay before symptom onset in humans and mice,
despite their profoundly different rates of development, raises
the possibility that stability of brain function, not brain devel-
opment per se, is compromised by the absence of MeCP2.
Previous attempts to create Mecp2-null mice
using Mecp2–/y ES cells were unsuccessful18. To
circumvent the problem of embryonic lethality,
we replaced exons 3 and 4 of Mecp2 in ES cells
with the same exons flanked by loxP sites21 (Fig.
1a). Mice homozygous or hemizygous for the
replacement were viable and fertile. Northern
blots showed the expected mature transcript
from the Mecp2lox locus (2.5 kb) plus a tran-
script in which the β-globin intron was
unspliced (3.3 kb; Fig. 1b). Early embryonic
deletion of the gene was achieved by crossing
Mecp2lox/lox females with deleter mice, which
express Cre ubiquitously22. Southern blots
showed that recombination between loxP sites
had occurred in all female offspring carrying the
deleter transgene and the Mecp2lox allele (Fig.
1d), leading to deletion of all but the amino-ter-
minal eight amino acids of MeCP2. When
Mecp2+/– females were mated with wild-type
C57BL/6 males, equal numbers of wild-type and
Fig. 1 Disruption of mouse Mecp2 using Cre-loxP technol-
ogy. a, Maps of the genomic locus, targeting vector, targeted
locus and recombined locus after exposure to Cre. b, North-
ern-blot analysis of RNA from brain, kidney and liver of wild-
type male (+/y), floxed male (lox/y), Mecp2-null male (–/y),
wild-type female (+/+) and female heterozygous for the null
allele (+/–) probed with a 3.2-kb NcoI fragment including
exons 3 and 4 of Mecp2. Bands A (10 kb) and D (2 kb) are
seen in wild-type tissue, whereas bands B (3.3 kb) and C (2.5
kb) are due to transcription of the floxed Mecp2 allele. No
Mecp2 mRNA is detected in the null males. Equal loading of
RNA is demonstrated by hybridization of the same blot to an
S26 ribosomal protein mRNA probe. c, Western blots of brain
protein from wild-type, floxed and null mice. No MeCP2 pro-
tein is detected in Mecp2-null brain. d, Southern blots of
DNA from tails of a single litter derived from a cross between
a Mecp2lox/lox female and a male carrying the X-linked
deleter transgene. Females, but not males, have deleted the
floxed allele in tail cells as expected. e, Southern-blot analysis
of tail DNA from mice born to a cross between an Mecp2+/–
female and a wild-type male. Half of males are expected to
be Mecp2–/y.
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Mecp2–/y males were born (Fig. 1e). No Mecp2 mRNA or protein
was detected in tissues from Mecp2–/y mice (Fig. 1b,c). We
obtained Mecp2–/– females by crossing Mecp2+/–, deleter+/–
females with Mecp2lox/y males (data not shown). The viability of
Mecp2-null animals proves that absence of MeCP2 does not cause
embryonic lethality in mice, contrary to a previous conclusion18.
The inviability of chimeric embryos containing Mecp2-null ES
cells seen previously may be due to adverse effects of the inserted
lacZ transgene on linked genes, or to epigenetic changes that
reduce pluripotency arising during ES proliferation in the
absence of MeCP2.
Mecp2-null male and female mice showed no initial pheno-
type, but both developed a stiff, uncoordinated gait and
reduced spontaneous movement between three and eight
weeks of age (Fig. 2a). Most animals subsequently developed
hindlimb clasping (Fig. 2b) and irregular breathing. Uneven
wearing of the teeth and misalignment of the jaws was also fre-
quent. Testes of Mecp2-null males were always internal. Neither
motor defects nor sensory defects were detected, but some
affected animals failed to respond to sound. Pathological
analysis of symptomatic animals revealed no obvious histolog-
ical abnormalities in a range of organs. In particular, the brain
showed no unusual features of cortical lamination, ectopias or
other abnormalities (Fig. 2c). Variable progression of symp-
toms lead ultimately to rapid weight loss and death at approxi-
mately 54 days (Fig. 2a).
A distinct feature of the phenotype was varying body weight,
which was dependent on genetic background. The Mecp2-null
mutation on a C57BL/6 background gave rise to animals that
were substantially underweight from four weeks with full pene-
trance (Fig. 3a–c). After crossing to a 129 strain, however, F1 ani-
mals showed a reverse effect. Instead of losing weight, Mecp2–/y
mice were the same weight as wild-type littermates until eight
weeks, when survivors became significantly heavier than siblings
(Fig. 3d) with an obvious increase in deposited fat. Other aspects
of the phenotype, including behavioral defects, were not affected
by altered genetic background. These data indicate the presence
of one or more modifier genes that mediate the effects of MeCP2
on body weight.
Mecp2 is expressed in many mouse tissues, but the phenotype
of Mecp2-null mice suggests neurological defects. To test whether
the effects of MeCP2 loss are specific to brain, the mutation was
combined with the nestin-Cre transgene23, which is highly
expressed in neuronal and glial cells. Southern blots confirmed
that Mecp2lox was approximately 65% deleted in brain (85% in
cerebellum), but 10% deleted or less in other somatic tissues (Fig.
3e). The phenotype of mice with extensive deletion of Mecp2 in
brain was indisinguishable from that of Mecp2-null mice. The
low frequency of Mecp2 deletion in non-brain tissues is unlikely
to contribute to the phenotype, as Mecp2+/– females are mosaic
for Mecp2 expression due to X-chromosome inactivation, yet
show no phenotype at this age. These data indicate that the major
features of the Mecp2-null phenotype, including reduced move-
ment, abnormal gait, limb clasping, low weight (Fig. 3f), internal
testes, uneven wearing of teeth and lethality, are probably due to
absence of MeCP2 in neuronal and/or glial cells.
The brain-specific effects of Mecp2 deletion may be due to
compensation for lack of MeCP2 in other tissues by a different
methyl-CpG binding repressor. Mbd2 is a component of the
MeCP1 histone deacetylase complex, which also represses tran-
scription20. As Mbd2–/– mice are viable and fertile24, we tested for
a possible interaction between MeCP2 and Mbd2 by combining
the Mecp2-null and Mbd2-null mutations. Double-mutant ani-
mals showed the same onset of symptoms and mortality as sin-
gle-mutant Mecp2-null mice, providing no evidence for a genetic
interaction between Mecp2 and Mbd2 (Fig. 4a).
We further analysed repression of methylated reporter genes
in tail fibroblast cell lines from wild-type mice and mice lack-
ing Mecp2, Mbd2, or both. Repression was only marginally
reduced in Mecp2–/y cells (∼ 5% of the non-methylated control)
compared with wild-type cells (∼ 2%; Fig. 4b). Mbd2–/– cells, in
contrast, repressed methylated reporter genes inefficiently
(25–30% of non-methylated control24), but this incomplete
repression was unaltered in double-mutant Mbd2–/–, Mecp2–/y
cells. By these assays, therefore, methyl-CpG–dependent
repression in tail fibroblasts is due to Mbd2, and MeCP2 has a
minimal role. Expression of exogenous MeCP2 did, however,




































0 20 40 60 80 100 120
   

























 * B6/129 male
ko symptom free, n=22
wt symptom free, n=12
ko survival, n=30
wt survival, n=12
+/y male –/y male –/y male
age (months)
Fig. 2 Phenotypes of mice with the
Mecp2-null mutation. a, Cumulative
plot showing percentage of wild-type
(open symbols) and hemizygous or
homozygous Mecp2-null animals
(filled symbols) that survived (trian-
gles) or remained free of obvious neu-
rological symptoms (circles) with
increasing time. Most data concerns
Mecp2–/y males on a C57BL/6 back-
ground, but the timings for Mecp2–/y
males crossed with 129 mice (*) and for
Mecp2–/– females (#) are highlighted.
b, Delayed onset hind limb clasping in
Mecp2–/y males. The left and middle
panels show normal spreading of
hindlimbs in wild-type and six-week
mutant males, respectively. Right,
limb-clasping phenotype in a mutant
male aged 7 weeks. c, Sections show-
ing histology of cerebral cortex of a
10-week Mecp2–/y mouse with pro-
nounced neurological symptoms (KO)
and an age-matched wild-type control
(WT) stained with hematoxylin and
eosin. Scale bar, 50 µm. d, Histogram
showing fraction of female mice het-
erozygous for the Mecp2-null muta-
tion that exhibit neurological
symptoms in different age groups
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MeCP2 can act as a methyl-CpG–dependent repressor in this
system (Fig. 4b). The combined genetic and biochemical
results indicate that Mbd2 and MeCP2 function in indepen-
dent pathways. It remains possible that another methyl-CpG
binding repressor (for example, Mbd1; refs. 25,26) might com-
pensate for absence of MeCP2.
Although Mecp2+/– female mice initially showed no symptoms
and raised normal litters, they acquired the inertia and hindlimb
clasping phenotypes at ages greater than three months (Fig. 2d).
By nine months of age, about one-half of the heterozygous mice
showed unambiguous symptoms, often including breathing
irregularities, but some remained asymptomatic at one year. The
overlapping delay seen in mice and humans before onset of the
effects of Mecp2 mutation is unexpected given the different tim-
ing of their developmental programmes. The mobility of affected
animals was quantified using an open field test27. Symptomatic
heterozygotes visited fewer squares, spent more time being
immobile and reared less than age-matched wild-type controls
(Table 1). This was not due to heightened anxiety, as fecal bolus
counts, grooming times and time spent in different zones of the
field were similar to those of controls. Unlike Mecp2-null ani-
mals, heterozygotes did not undergo rapid deterioration, raising
the possibility that the Mecp2+/– condition can, like RTT, exhibit
long-term stability.
Fig. 4 Absence of obvious genetic or
biochemical interactions between
MeCP2 and the methyl-CpG binding
repressor Mbd2. a, Cumulative plot
comparing percentage of Mecp2–/y
(open symbols) and Mecp2–/y,
Mbd2–/– double-mutant animals
(filled symbols) that survived (trian-
gles) or remained free of neurologi-
cal symptoms (circles) with
increasing time. The profiles for the
two genotypes were determined in
parallel using littermates on a
C57BL/6×129 background (B6/129)
and are independent of the data
shown in Fig. 2a. b, Repression of a
methylated reporter construct con-
taining the pGL2 promoter relative
to the same reporter unmethylated,
is only slightly less efficient in Mecp2–/y cells than in wild-type cells. Relative repression is significantly less efficient in Mbd2–/– cells and this efficiency is not reduced in
double-mutant Mecp2–/y, Mbd2–/– cells. Co-transfection with an MeCP2 expression construct (right) restores repression of the methylated reporter gene.
Fig. 3 Effects of Mecp2 deletion on body
weight. a, Body weight from birth of indi-
vidual males from a single litter. Mecp2-
null males are significantly smaller than
wild-type littermates from around wean-
ing (∼ 3 weeks of age). b,c, Body weight
from weaning of two different litters on a
C57BL/6 (B6) background, showing reduced
weight of Mecp2-null animals (open sym-
bols) compared with wild-type littermates
(filled symbols). d, Body weight of Mecp2–/y
(open symbols) and wild-type (filled sym-
bols) littermates on a C57BL/6×129 F1 back-
ground. The two mutant animals (of 4 in
the litter) surviving beyond 7 weeks gained
weight relative to littermates. e, Southern-
blot analysis of tissue DNA from a male
mouse containing the nestin-Cre transgene
and the floxed allele of Mecp2. The propor-
tion of recombination in each tissue is cali-
brated by comparison with band intensities
in DNA from a heterozygote for the wild-
type and null alleles (het), where the ratio
is known to be 1:1. The tissues tested are
brain (minus cerebellum) (Br), cerebellum
(Ce), thymus (Th), heart (He), lung (Lu),
liver (Li), spleen (Sp), kidney (Ki), seminal
vesicles (Sv), testis (Te), skeletal muscle (Sk)
and tail (Ta). Percentage of chromosomes
deleted is shown below each lane. f, Body
weight from weaning of C57BL/6
Mecp2lox/y males (open symbols) carrying a
nestin-Cre transgene that causes deletion
of Mecp2 predominantly in brain (e) com-
pared with wild-type littermates (filled
symbols). Reduced weight like that seen for
Mecp2–/y males is apparent, indicating a
neurological origin for this component of
the phenotype. d–f, Animals dying natu-
rally (†) and those sacrificed for experimen-
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The results of this and the
accompanying paper28 show
that mice with the Mecp2-null
mutation are a valid model for
human RTT, as delayed onset
of a neurological crisis affecting
gait, posture, breathing and
spontaneous movement is seen
in both conditions. These data
support the view that RTT is
primarily a neurological dis-
ease, but in other respects they
challenge current perceptions
of this condition. First, it has
been thought that RTT is
caused by mutations that
impair the function of MeCP2, but do not inactivate it. Advanced
mouse development in the absence of MeCP2, plus evidence that
certain human MECP2 mutations apparently abolish the func-
tion of the protein29,30, argue that many RTT patients may be
heterozygous for what are effectively null mutations in MECP2. A
second unexpected finding is that the absolute time of onset of
symptoms overlaps in human and mouse MECP2 heterozygotes.
This approximate correspondence in real time, not developmen-
tal time, argues against a developmental defect due to MeCP2
deficiency, as this would arise much earlier in rapidly developing
mice. An alternative hypothesis is that neurogenesis can be
accomplished in the absence of MeCP2, but that the resulting
brain cells, whether human or mouse, are functionally unstable.
Brain function in MECP2-null males of either species may there-
fore decline steeply, leading to early symptoms and death. Het-
erozygous females, on the other hand, have many brain cells that
express wild-type MeCP2 and would therefore take longer to
reach the level of brain cell dysfunction at which neurological
symptoms appear.
Methods
Conditional gene targeting construct. The targeting vector was designed to
flank the coding sequences in exons 3 and 4 (all but the first 8 aa of the pro-
tein) with loxP sites, also adding an additional intron and polyadenylation
signal from the human β-globin gene and a neomycin resistance gene for
selection of transfected ES cells. The targeting vector was constructed using
a 7.2-kb BamHI genomic fragment subcloned in pBSIIKS+ from a 40-kb
129 mouse cosmid. The 3´ BamHI site is present in the mouse genome,
with the 5´ site coming from the cosmid polylinker. The 5´ loxP site and
diagnostic restriction sites were inserted into an NcoI site in intron 2 using
oligonucleotides. A second NcoI site in the 3´ UTR was used to insert a 2.8-
kb BamHI-XbaI fragment containing intron 2 and the polyadenylation sig-
nal of human β-globin, followed by a 1.2 kb TK-neo cassette flanked by
loxP sites (“floxed”; a gift from A. Smith). This resulted in a targeting vector
with ∼ 2.8 kb of 5´ homology, 1.2 kb of 3´ homology and a 3.2-kb floxed seg-
ment. The vector was linearized for transfection at the 3´ end using XhoI.
ES cell culture and gene targeting. We carried out gene targeting in the ES
cell line E14 TG2a (A. Smith) which is derived from the mouse substrain
129/Ola. Cells were grown on gelatinized dishes without feeder cells in the
presence of recombinant human LIF (a gift from A. Smith) in Glasgow
MEM (Life Technologies) supplemented with 10% fetal bovine serum
(Globepharm), 1×MEM non-essential amino acids, sodium pyruvate (1
mM), β-mercaptoethanol (50 µM; all Life Technologies). ES cells (5×107
cells) were transfected with the linearized targeting vector (250 µg DNA in
0.8 ml HEPES buffered saline) by electroporation (800 V, 3 µF, BioRad
Gene Pulser) and plated in 10-cm dishes at 5×106 cells per dish. Correctly
targeted clones were identified by Southern-blot analysis. For targeting at
the 3´ end, ES-cell DNA was digested with BamHI and the blots probed
with a 1.2-kb NcoI–BamHI fragment. The 11-kb wild-type band was
replaced in targeted clones by a 8.2-kb band from the floxed allele. To check
for the presence of the 5´ loxP site, the same BamHI-digested DNA was
probed with a 0.95-kb XbaI-NcoI fragment. The wild-type allele gave an
11-kb band, the targeted gene without 5´ loxP site, a 15-kb band, and the
targeted gene with 5´ loxP site, a 6.8-kb band.
Generation and breeding of chimeric mice. Correctly targeted ES cell clones
for injection into blastocysts were passaged the day before injection and
injected into blastocysts from naturally mated C57BL/6 females at 3.5 days
post coitum. Injections were performed in M2 medium (Sigma) with 10–15
ES cells being injected into each blastocyst before transfer to pseudopregnant
recipient females (6–12 blastocysts per recipient). Chimeric pups were identi-
fied by their agouti coat color and, on maturity, were mated with C57BL/6
mice. As Mecp2 is X-linked, all agouti F1 females were heterozygous for the
floxed allele, and this was confirmed by Southern blot. We crossed heterozy-
gous females with wild-type C57BL/6 males (F2 generation). Resulting hem-
izygous males were crossed to heterozygous females to generate homozygous
females (F3) and the line was then maintained in the homo/hemizygous state.
Cre-expressing mice and deletion of Mecp2. We obtained deleter mice22,
which carry a ubiquitously expressed Cre transgene on the X chromosome.
Male deleter mice were crossed with homozygous floxed females. All
female pups were Mecp2+/– and hemizygous for cre. All male pups were
hemizygous for the Mecp2lox allele. Mecp2+/– females were crossed with
wild-type C57BL/6 males to give Mecp2+/– or Mecp2+/+ females and
Mecp2+/y or Mecp2–/y males. The three Mecp2 alleles were identified by
Southern-blot analysis by digesting with BamHI and probing with the 1.2-
kb NcoI-BamHI 3´ probe (Mecp2+, 11 kb; Mecp2lox, 8.2 kb; Mecp2–, 1.2 kb).
Heterozygous nestin-Cre males23 were crossed with Mecp2lox/lox females to
generate males that had Mecp2 deleted in neural and glial cells. Animals
carrying the nestin-Cre transgene were identified by PCR on tail genomic
DNA (forward primer CreF, 5´–GACCGTACACCAAAATTTGCCTG–3´;
reverse primer CreR, 5´–TTACGTATATCCTGGCAGCGATC–3´; 5 min at
94 °C, 30 cycles of 30 s at 94 °C, 30 s at 64 °C, 45 s at 72 °C, followed by 5
min at 72 °C. The 465-bp product was visualized by running on a 1.5%
TAE agarose gel. Various tissues were used to make genomic DNA, which
was digested with BamHI, Southern blotted and probed with the NcoI-
BamHI 3´ Mecp2 probe. The extent of deletion in each tissue was quantified
using ImageQuant software (Molecular Dynamics), correcting for back-
ground and higher intensity signal from the smaller, deleted allele.
Southern-, northern- and western-blot analysis. Genomic DNA was prepared
from ES cell clones and tail tips by standard procedures. RNA was prepared
from mouse tissues using TriReagent (Sigma) following homogenization in an
UltraTurrax homogenizer. RNA was made from the lysates according to the
manufacturer’s protocol. Southern and northern blots were prepared by stan-
dard procedures. Radioactive probe was detected using a PhosphoImager
(Molecular Dynamics) and quantitated using ImageQuant software.
We carried out western-blot analysis on total brain extracts from wild-type,
floxed and mutant mice. Brains were collected in cold PBS and transfered to
cold Laemmli sample buffer without SDS (60 mM Tris Cl, pH 6.8, 100 mM
DTT, 10% glycerol). The tissue was then homogenized using an UltraTurrax
on high speed for 10 s before adding SDS to 2%. Lysates were sonicated
briefly, boiled for 5 min and centrifuged for 10 min at 13,000 r.p.m. Super-
Table 1 • Performance of wild-type and Mecp2+/– females in open field testing
Wild typea Heterozygotea P=b
Number of animals 7 11 –
Total no. squares visited 139 (16) 73 (14) 0.0087
% Squares visitedc outer 80.8 (2.7) 80.4 (4.3) NS
middle 14.6 (2.3) 15.4 (4.1) NS
inner 4.5 (0.8) 4.3 (1.4) NS
Number of rears 15.9 (4.4) 4.3 (1.3) 0.0078
Number of fecal boli 2.7 (0.8) 3.6 (0.5) NS
Time spent grooming (s) 14.5 (2.8) 9.2 (1.9) NS
Time spent immobile (s) 27.9 (5.2) 90.3 (18.2) 0.0172
aMean values are shown followed by the standard error of the mean in brackets. bValues for wild-type and heterozy-
gous females were compared using an unpaired t-test. Where a significant difference was found at the 95% confidence
level, the P value is shown. NS indicates 'not significant'. cThe squares of the open field apparatus were classified as
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natant aliquots were run on 12.5% SDS–PAGE gels with 10 µg protein per
lane. Western blots with anti-MeCP2 rabbit polyclonal antibody (Upstate
Biotech) were carried out according to the manufacturer’s instructions and
visualized on Hyperfilm using the ECL system (Amersham).
Transient transfection assays. We used tail fibroblasts with the following four
genotypes: Mecp2+/y,Mbd2+/+; Mecp2–/y,Mbd2+/–; Mecp2+/y,Mbd2–/–; and
Mecp2–/y,Mbd2–/–. Mbd2–/– cells were obtained as described24. Mecp2–/y cells
were obtained by immortalizing tail fibroblasts from Mecp2lox/y males on
either an Mbd2+/– or Mbd2–/– background and subsequently transfecting with
a CMVcre transgene. Cell clones that had deleted Mecp2 were then selected.
Cells were grown to approximately 50% confluence and transfected using
Lipofectamine according to the manufacturer's instructions (Life Technolo-
gies). Each well of a 6-well plate was transfected with 2 µg of either M.SssI
methylated or unmethylated pGL2-Promoter plasmid plus pRL-SV40 control
plasmid (50 ng; Promega). Where necessary, a CMV-Mecp2 expression con-
struct (100 ng) was co-transfected. Luciferase levels were measured after ∼ 40 h
using the Dual Luciferase Assay kit according to manufacturer's instructions
(Promega). Sample values were obtained according to the following formula:
(luciferase sample–luciferase control)/(renilla sample–renilla control) where
control values are obtained from untransfected cells. Relative luciferase values
are defined as the sample value obtained using a methylated pGL-Promoter
plasmid divided by the sample value obtained using the unmethylated pGL-
Promoter plasmid.
Phenotypic testing and pathological analysis. Mice were analysed using the
SHIRPA primary screen test series31 that was developed for rapid phenotype
testing in mutation screens. Motor defects were tested by assaying grip
strength, wire maneuver and limb tone and sensory defects by visual placing,
toe pinch, corneal and pinna reflexes. Hearing was tested by the click box test.
For pathological analysis, organs were examined macroscopically and solid
organs were weighed. All organs sampled for histological analysis were
embedded in paraffin wax, sectioned (4 µm) and stained with hematoxylin
and eosin. Brain and spinal cord were additionally stained with Luxol fast blue
cresyl violet stains. Tissues examined included heart, larynx, lung, liver, pan-
creas, tongue, esophagus, stomach, intestine, thymus, spleen, kidney, adrenal
gland, testes, skeletal muscle, brain and spinal cord. The open field apparatus
consisted of a rectangular box 1.5×1.0×0.2 m in size, divided into 48 (8×6)
equal squares. The behavioral parameters registered during a 5 min session
were as follows: (i) the total number of entries into squares (subdivided into
movement in outer, middle and inner zones); (ii) the number of rears (stand-
ing on hind legs with forelegs in air or against the wall); (iii) defecation; (iv)
time spent grooming; and (v) time spent immobile.
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